Connect with us

Artificial Intelligence

Insilico Medicine pushes AI-discovered IPF drug into final-stage human trials

Published

on

AI drug for IPF

From algorithm to late-stage clinic: a milestone for AI-driven pharma

Insilico Medicine has pushed its lead asset into Phase III human trials. The drug, rentosertib, targets idiopathic pulmonary fibrosis (IPF) — a devastating lung disease with a median survival of just two to four years after diagnosis. This is no small step. It marks one of the few times an AI-discovered molecule has moved beyond early safety checks into large-scale efficacy testing.

The company’s proprietary platform, Pharma.AI, did the heavy lifting. It identified the biological target, designed the molecule, and predicted how it would behave in the body. Now, regulators and patients will see if those predictions hold up at scale.

What is IPF and why rentosertib matters

IPF scars lung tissue relentlessly. Patients lose the ability to breathe properly. Existing drugs slow progression but don’t stop it — and they come with side effects. Rentosertib works differently. It inhibits an enzyme called TNIK (TRAF2- and NCK-interacting kinase), which sits at the crossroads of several pathways driving fibrosis, inflammation, and aging-related tissue damage.

A Phase IIa trial, conducted across 22 sites in China, tested 71 patients. One group got a placebo. Another received 30 mg or 60 mg daily doses of rentosertib for 12 weeks. The results were striking: patients on the 60 mg dose gained an average of 98.4 mL in forced vital capacity (a key measure of lung function), while the placebo group lost 20.3 mL. The U.S. Food and Drug Administration (FDA) had already granted orphan drug designation in February 2023.

How PandaOmics found the target no one else saw

The discovery pipeline started with PandaOmics, one of three engines inside Pharma.AI. This system chews through genomics, clinical data, scientific literature, and patent filings. It builds biological network models and applies causal inference — a statistical method that goes beyond correlation to identify likely drivers of disease.

PandaOmics flagged TNIK as the prime target for IPF intervention. That was unconventional. Most IPF drugs target receptor tyrosine kinases. TNIK sits deeper in the signaling web, regulating pathways like Wnt, TGF-β, Hippo/YAP-TAZ, JNK, and NF-κB. The algorithm also scored TNIK high on a hallmarks-of-aging framework, linking it to chronic inflammation, fibrosis, and cellular senescence.

Feng Ren, PhD, Co-CEO and Chief Scientific Officer of Insilico Medicine, put it plainly: “Rentosertib was not discovered by starting from a conventional target and simply screening more compounds. It came from a biology-first, ageing-informed AI workflow.”

Chemistry42: generative design, not library screening

Once the target was locked, the Chemistry42 engine took over. This is not your typical high-throughput screening, where robots test millions of compounds from a library. Chemistry42 builds molecules from scratch using Generative Tensorial Reinforcement Learning. It designs structures that fit the target protein’s pocket while balancing drug-like properties — solubility, metabolism, toxicity.

The system generated just 79 physical molecules for testing. The team selected the 55th iteration for preclinical development. From project start to preclinical candidate nomination: 18 months. That’s fast by industry standards. The underlying methodology, called GENTRL, was published in Nature Biotechnology back in 2019.

Proteomic clocks and senescence markers in the clinic

Insilico didn’t stop at standard clinical endpoints. The Phase IIa trial included exploratory proteomic analysis using aging-clock frameworks. Tools like ProtAge, OrganAgechrono, and ipfP3GPT tracked predicted biological age changes. The team compared treatment-responsive proteins against UK Biobank trajectories.

Mortality-risk clocks (PAC and OrganAgemortality) provided additional layers of analysis. SenMayo and CellAge signatures measured senescence and senescence-associated secretory phenotype activity. Peer-reviewed work in Aging and Disease confirmed that TNIK inhibition produces senomorphic effects — reducing extracellular matrix remodeling markers.

Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine, framed the bigger picture: “This program began with the hypothesis that ageing biology could help identify powerful targets for major diseases. It has now advanced through target discovery, molecular design, preclinical validation, Phase I safety, randomised Phase IIa clinical data, and into Phase III development. For the AI drug discovery field, this is no longer only a speed story — it is a clinical translation story.”

What Phase III will test — and why it matters for AI in biopharma

The upcoming Phase III trial will enroll hundreds of patients across multiple countries. It will measure lung function, progression-free survival, and safety over a longer period. Success would validate not just rentosertib, but the entire AI-driven approach to drug discovery.

Several publications document the journey so far. Nature Biotechnology covered the discovery-to-clinic arc. The Journal of Medicinal Chemistry published the structural biology — including the TNIK kinase domain co-crystal structure. Nature Medicine reported the Phase IIa data.

For the broader industry, this is a test case. Can AI really originate new biology and new chemistry, not just accelerate old methods? The answer will come from patients, regulators, and the data. Phase III is where that answer starts taking shape.

Want to learn more about AI in drug discovery? Check out our coverage of NVIDIA BioNeMo’s role in accelerating research and how generative AI is reshaping clinical trials.

Continue Reading

Artificial Intelligence

XDOF, three months out of stealth, is already closing in on a $1.2B Series B

Published

on

XDOF Series B

From stealth to unicorn talk in record time

Three months. That’s how long XDOF has been out in the open. And already, the robotics data startup is in late-stage conversations to raise a Series B at a valuation hovering around $1.2 billion, according to multiple sources familiar with the negotiations. The round would be led by 8VC.

Not bad for a company that didn’t even exist publicly until June.

XDOF was co-founded in 2024 by UC Berkeley researchers Philipp Wu (CEO) and Fred Shentu (CTO). Their origin story traces back to a research project called GELLO — a low-cost teleoperation system that lets a human operator control a robotic arm from a distance. The goal? Generate training data for robots. That work produced an influential paper in robotics and, eventually, a company.

The startup’s Series A, a $70 million round announced in June, drew participation from Thrive Capital, Andreessen Horowitz, Lux, and Spark Capital. At the time, XDOF wasn’t planning to raise again so soon. But the market had other ideas.

Why investors are knocking on XDOF’s door

The reason for the sudden interest? Growth. Real, measurable growth.

XDOF’s annualized revenue is approaching $50 million, sources say. That kind of traction, so soon after a Series A, tends to make venture capitalists sit up and take notice. It also tends to make them pick up the phone.

“They weren’t out raising,” one person familiar with the situation told TechCrunch. “The VCs came to them.”

Terms aren’t final, and the total capital being raised remains unclear. TechCrunch couldn’t confirm whether the $1.2 billion valuation includes the new funding or sits on top of it. Both XDOF and 8VC declined to comment.

The Scale AI for physical robots

XDOF’s pitch is straightforward: it builds the data pipelines, collection tools, and annotation systems that frontier AI labs and robotics companies would rather not build themselves. Think of it as an outsourced data-supply chain for the robotics industry.

Investors describe XDOF as the Scale AI or Mercor of physical robotics — a nod to the data-labeling giants that powered the AI boom. The comparison makes sense. Large language models trained on the entire internet. Physical robots? They don’t have that luxury. There’s no massive, ready-made dataset of real-world robot interactions sitting online. That scarcity makes data collection the critical bottleneck on the road to general-purpose machines.

Wu felt that bottleneck firsthand as a PhD student. His research on how robots learn from large datasets kept hitting the same wall: “large-scale data to work with” simply didn’t exist, he told TechCrunch in June.

Building the ABC dataset

XDOF is tackling that problem head-on. The startup is partnering with UC Berkeley’s AI Research lab to release what it believes is the largest collection of high-quality robot training data ever assembled. The dataset is called ABC.

Collecting that data requires a hybrid approach. XDOF combines remote robot teleoperation with human collectors who wear sensors to record everyday tasks. Think folding clothes. Flattening boxes. The mundane, physical chores that robots still struggle to master.

The company plans to hire and train teams of data collectors around the world. Two main roles are emerging:

  • Teleoperators who steer robots remotely to demonstrate tasks
  • Egocentric operators who wear body sensors to capture natural movement data

Early traction and the competitive landscape

XDOF has already signed up 20 customers, including several frontier AI labs, according to previous statements to TechCrunch. That customer base, combined with the revenue trajectory, helps explain the valuation chatter.

But XDOF isn’t alone in this niche. Other startups chasing real-world data for robot training include Mecka AI. And the human-data platforms that started with LLMs — like Scale AI and Micro1 — are expanding beyond text and images into physical domains.

The race to build the data infrastructure for physical AI is heating up. Whoever wins it will effectively control the fuel supply for the next generation of robots. That’s a position worth paying up for.

Whether the $1.2 billion valuation holds remains to be seen. Deals at this stage can shift. But the fact that XDOF is even in this conversation — three months after emerging from stealth — says something about the demand for what it’s building.

For more on how data is shaping the future of AI, check out AI data labeling trends and robotics funding rounds in 2024.

Continue Reading

Artificial Intelligence

New York City Pulls AI From Younger Classrooms—Here’s Why It Matters

Published

on

NYC AI ban

New York City Just Hit Pause on AI in Classrooms

New York City Public Schools is drawing a hard line: no generative AI for students from 2-K through eighth grade during the 2026-2027 school year. That’s over half a million kids walking into classrooms next week without access to AI-powered tools.

The district says it will remove software with student-facing AI features and block AI companion chatbots. High schoolers? They’re exempt. This isn’t a blanket ban—it’s a targeted move to decide when kids should actually start using the technology.

Mayor Zohran Mamdani put it bluntly: “The tech industry wants us to believe that AI-powered early education is not only inevitable, but necessary. We do not see it that way.”

Why NYC Is Worried About AI for Younger Students

The fear isn’t just that a kid will ask ChatGPT to write an essay. City officials want younger students to build core skills—critical thinking, creativity, communication—without leaning on AI as a crutch. They’re also pushing for stronger human connections in classrooms, not another screen.

Schools Chancellor Kamar Samuels said the city refuses to assume that innovation automatically equals more technology in front of students. It’s a deliberate slowdown, and it follows last year’s bell-to-bell cellphone ban that already limits device use during school hours.

What Happens When Kids Reach High School?

AI doesn’t vanish once students hit ninth grade. Instead, the district plans to roll out AI literacy classes twice a year. The goal? Teach teenagers how to think critically about the technology before they become dependent on it.

That’s a different approach from just saying no. It’s about timing—letting younger minds develop without AI, then giving older students the tools to question it.

The National Battle Over AI in Education

NYC’s decision sits at the center of a much bigger fight. The White House has pushed educators to embrace AI responsibly. Some teachers already use it to craft lesson plans, give feedback, or break down tough subjects. But not everyone’s on board.

The Department of Health and Human Services recently gathered childhood experts to talk about excessive screen time. Officials have also called for tougher safeguards around social media and AI. The message? Kids are spending too much time in front of screens, and AI might make it worse.

A Bold Experiment With Zero AI

Here’s what makes NYC’s move so interesting: instead of asking how much AI younger students should use, the largest school district in the country is starting with none. For one academic year, they’re testing whether classrooms are better off with AI kept outside the door.

That’s a radical stance, and it’s not without critics. Some educators argue AI can personalize learning or help struggling students catch up. But NYC is betting that a year without AI will reveal what kids actually need—not what tech companies think they need.

What This Means for Parents and Teachers

If you’re a parent in NYC, expect changes. AI-based apps may disappear from your child’s school day. Teachers will need to plan lessons without generative AI tools. And students in grades 2-K through 8 will rely more on traditional methods—paper, pencils, and human interaction.

For teachers elsewhere, this could be a signal. NYC is the biggest district to take this stance, and its findings could shape policies nationwide. The next year will be watched closely by educators, policymakers, and tech giants alike.

What Happens Next?

The district will spend the year studying how generative AI affects students before deciding what comes next. That research could lead to a permanent ban, a partial rollout, or something entirely different.

For now, NYC is making a statement: childhood shouldn’t be an AI beta test. Whether that’s the right call or a step backward, we’ll know more in 2027. Until then, the debate over AI in schools just got a lot more interesting.

If you’re curious about how AI is shaping other areas, check out our take on AI in education trends or classroom technology policies.

Continue Reading

Artificial Intelligence

Meta’s Muse Spark 1.3 takes on GPT-5.6 and Claude — but can it really win?

Published

on

Muse Spark 1.3

Meta just fired a serious shot in the AI arms race

The company quietly unleashed Muse Spark 1.3, its most advanced AI model to date, and it’s aiming straight at the top dogs. Developers can already access and pay for the update, which Meta says represents a massive leap forward in performance.

It won’t stay confined to the developer sandbox for long. Over the coming weeks, the model will roll out across Instagram, Facebook, and the Meta AI assistant — putting it in front of billions of everyday users.

What makes Muse Spark 1.3 actually different?

Meta’s Chief AI Officer, Alexandr Wang, didn’t mince words. He called this “the biggest jump so far on model performance,” pointing to serious gains in two areas: coding and agentic tasks — the kind where the AI acts on your behalf rather than just answering questions.

But here’s the catch. Wang told Bloomberg that Muse Spark 1.3 is competitive with Anthropic’s Claude Fable 5.1 and even beats OpenAI’s GPT-5.6 Sol at coding. That’s a bold claim, especially with OpenAI’s upcoming Astra model lurking in the wings.

Take those comparisons with a grain of salt, though. Benchmarks can be gamed, and a model that crushes one test might stumble on a totally different task. Real-world performance is what actually matters.

Efficiency gains under the hood

Wang broke down a few upgrades that set Muse Spark 1.3 apart:

  • 25% fewer tokens needed to complete the same job — meaning lower costs and faster responses
  • Multi-workflow handling — it can juggle several tasks at once instead of forcing separate sessions
  • Better context retention across long, complicated instructions
  • Self-awareness of limits — the model now pauses to ask for clarification before taking any irreversible action

That last point is quietly important. AI that knows when it doesn’t know is a big step toward trustworthiness, especially for agentic use cases.

Pricing stays flat, adoption explodes

Here’s something developers will appreciate: Meta isn’t raising prices. Muse Spark 1.3 costs the same as its predecessor, Muse Spark 1.2. That’s a smart move when rivals are hiking rates.

Wang told Bloomberg that adoption on Meta’s developer platform has been strong — some users are burning through trillions of tokens every week. Those numbers suggest real usage, not just hype.

What about open-source fans? Meta hasn’t decided whether it will release the model’s weights — the blueprint that lets outside developers build on top of it. The older Muse Spark 1.2 weights are still headed for release, but the new model’s future remains unclear.

The bigger picture: Meta’s spending spree continues

Meta is still pouring billions into AI infrastructure, and Muse Spark 1.3 is the clearest signal yet that the company believes it’s closing the gap with OpenAI and Anthropic. Whether that’s true or just corporate bravado will play out in the benchmarks and real-world deployments over the coming months.

For now, the model is available to developers, and the app rollout is imminent. If you’re building on Meta AI tools, this update is worth a serious look. And if you’re just a curious user, you’ll likely meet Muse Spark 1.3 in your Instagram feed sooner than you think.

One thing’s certain: the AI race just got a lot more interesting.

Continue Reading

Trending